Skip to main content

Table 1 Statistical comparison of DTG PK parameters when administered with and without DCV

From: No clinically significant pharmacokinetic interactions between dolutegravir and daclatasvir in healthy adult subjects

Plasma DTG PK parameter

Geometric mean (CV%)

Geometric least-squares mean ratio (90 % CI)

DTG alone

(treatment A)

(N = 12)

DTG + DCV

(treatment C)

(N = 12)

DTG + DCV vs

DTG alone

AUC0-τ (hr · μg/mL)

35.7 (34.7)

47.3 (26.3)

1.33 (1.11–1.59)

Cmax (μg/mL)

2.65 (32.0)

3.43 (24.5)

1.29 (1.07–1.57)

Cτ (μg/mL)

0.771 (41.3)

1.11 (36.6)

1.45 (1.25–1.68)

CL/F (L/hr)

1.40 (34.7)

1.06 (26.3)

0.753 (0.627–0.905)

t1/2 (hr)

13.9 (32.8)

16.2 (32.6)

1.17 (1.01–1.35)

  1. Abbreviations: AUC 0-τ area under the concentration-time curve over the dosing interval, C τ concentration at the end of the dosing interval, CI confidence interval, CL/F apparent clearance following oral dosing, C max maximum observed concentration, DCV daclatasvir, DTG dolutegravir, PK pharmacokinetic, t 1/2 terminal phase half-life
  2. Treatment A = DTG 50 mg once daily; treatment C = DTG 50 mg once daily plus DCV 60 mg once daily
Back to article page

BMC Infectious Diseases

ISSN: 1471-2334

Contact us